Equity Overview
Price & Market Data
Price: $1.65
Daily Change: +$0.01 / 0.61%
Daily Range: $1.55 - $1.78
Market Cap: $9,126,760
Daily Volume: 102,880
Performance Metrics
1 Week: -2.94%
1 Month: -12.23%
3 Months: -1.79%
6 Months: -59.33%
1 Year: -53.26%
YTD: -49.85%
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.